抗生素在炎症性关节炎和背景人群的诊断前一年和诊断后一年:全国性的药物使用研究
Maja S Kragsnaes1,2, Nickolaj Risbo3, Jens Kristian Pedersen1,2
1Department of Rheumatology, Odense University Hospital, Odense, Denmark.
Rheumatology (Oxford, England)
|August 27, 2024
概括
与一般人群相比,患有炎症性关节炎 (IA) 的人群使用抗生素的比例更高. 抗生素处方模式在IA诊断后发生了变化,在不同IA亚型中存在显著差异.
科学领域:
- 类风湿病学 类风湿病学
- 传染病流行病学 传染病流行病学
- 药学流行病学 药学流行病学
背景情况:
- 炎症性关节炎 (IA) 包括诸如类风湿性关节炎 (RA),牛皮性关节炎 (PsA) 和结性脊柱炎 (AS/SpA) 等疾病.
- 了解AI患者的抗生素使用模式对于疾病管理和公共卫生洞察至关重要.
研究的目的:
- 为了比较新诊断的IA患者的抗生素分发与背景人群 (BP) 的情况.
- 分析IA患者在诊断前后使用抗生素的变化.
主要方法:
- 利用丹麦全国性的登记册来识别IA患者 (RA,PsA,AS/SpA) 并匹配2010-2018年的对照.
- 在IA诊断前和后的一年内计算的患病率和总抗生素发放量.
- 在IA小组和BP之间比较抗生素的使用.
主要成果:
- 与BP相比,被诊断为IA的个人在诊断前显示出较高的抗生素分发率.
- 在IA患者的抗生素使用在诊断前三个月增加.
- 在诊断后,IA患者的抗生素开放率下降,但总开放量因IA亚型而异 (RA稳定,PSA下降,AS/SpA增加).
结论:
- 在随后患上IA的个体中,分发抗生素的频率更高.
- 抗生素利用模式在IA诊断后表现出明显的变化,在RA,PsA和AS/SpA之间有所不同.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
329
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
329
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


